Abstract
In last decades, the approach to treatment of lymphomas has undergone a revolutionary development. Since the discovery of rituximab, the first monoclonal antibody successfully used in the treatment of CD20+ lymphomas more than 20 years ago, a wide range of other immunotherapeutic approaches have been discovered significantly improving the prognosis of patiencs with refractory or relapsed disease.
Among che most important discoveries (in addition to monoclonal antibodies and their conjugates to cytotoxic agents) are bispecific antibodies, imine checkpoint inhibitors and T-lymphocyces expressing the chimeric antigen receptor. Despite the initial euphoria, even these modern approaches require consistent patient selection, their preparation, timing of treatment, and adequate management of complications to achieve optimal antitumor response.